Search Page

1

Cite

Share

Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).

Luke DR, Tomaszewski K, Damle B, Schlamm HT. Luke DR, et al. Among authors: schlamm ht. J Pharm Sci. 2010 Aug;99(8):3291-301. doi: 10.1002/jps.22109. J Pharm Sci. 2010. PMID: 20213839 Review.

Cite

Share

2

Cite

Share

Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients.

McLaughlin JM, Equils O, Somerville KT, Aram JA, Schlamm HT, Welch VL, Mardekian J, Barbers RG. McLaughlin JM, et al. Among authors: schlamm ht. Transpl Infect Dis. 2013 Aug;15(4):329-43. doi: 10.1111/tid.12063. Epub 2013 Mar 12. Transpl Infect Dis. 2013. PMID: 23489832

Cite

Share

3

Cite

Share

An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis.

Queiroz-Telles F, Goldani LZ, Schlamm HT, Goodrich JM, Espinel-Ingroff A, Shikanai-Yasuda MA. Queiroz-Telles F, et al. Among authors: schlamm ht. Clin Infect Dis. 2007 Dec 1;45(11):1462-9. doi: 10.1086/522973. Epub 2007 Oct 22. Clin Infect Dis. 2007. PMID: 17990229 Clinical Trial.

Cite

Share

4

Cite

Share

Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis.

Chai LY, Kullberg BJ, Earnest A, Johnson EM, Teerenstra S, Vonk AG, Schlamm HT, Herbrecht R, Netea MG, Troke PF. Chai LY, et al. Among authors: schlamm ht. PLoS One. 2014 Feb 28;9(2):e90176. doi: 10.1371/journal.pone.0090176. eCollection 2014. PLoS One. 2014. PMID: 24587262 Free PMC article. Clinical Trial.

Cite

Share

5

Cite

Share

Tissue distribution of anidulafungin in neonatal rats.

Ripp SL, Aram JA, Bowman CJ, Chmielewski G, Conte U, Cross DM, Gao H, Lewis EM, Lin J, Liu P, Schlamm HT. Ripp SL, et al. Among authors: schlamm ht. Birth Defects Res B Dev Reprod Toxicol. 2012 Feb;95(1):89-94. doi: 10.1002/bdrb.20347. Epub 2012 Feb 6. Birth Defects Res B Dev Reprod Toxicol. 2012. PMID: 22311649

Cite

Share

6

Cite

Share

Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.

Herbrecht R, Patterson TF, Slavin MA, Marchetti O, Maertens J, Johnson EM, Schlamm HT, Donnelly JP, Pappas PG. Herbrecht R, et al. Among authors: schlamm ht. Clin Infect Dis. 2015 Mar 1;60(5):713-20. doi: 10.1093/cid/ciu911. Epub 2014 Nov 19. Clin Infect Dis. 2015. PMID: 25414266 Clinical Trial.

Cite

Share

7

Cite

Share

Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.

Oude Lashof AM, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Schlamm HT, Rex JH, Kullberg BJ. Oude Lashof AM, et al. Among authors: schlamm ht. Antimicrob Agents Chemother. 2012 Jun;56(6):3133-7. doi: 10.1128/AAC.05841-11. Epub 2012 Mar 26. Antimicrob Agents Chemother. 2012. PMID: 22450974 Free PMC article.

Cite

Share

8

Cite

Share

Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.

Bow EJ, Vanness DJ, Slavin M, Cordonnier C, Cornely OA, Marks DI, Pagliuca A, Solano C, Cragin L, Shaul AJ, Sorensen S, Chambers R, Kantecki M, Weinstein D, Schlamm H. Bow EJ, et al. BMC Infect Dis. 2015 Mar 17;15:128. doi: 10.1186/s12879-015-0855-6. BMC Infect Dis. 2015. PMID: 25887385 Free PMC article. Review.

Cite

Share

9

Cite

Share

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, Jafri H, Arrieta AC, Klein NJ, Lutsar I. Walsh TJ, et al. Antimicrob Agents Chemother. 2010 Oct;54(10):4116-23. doi: 10.1128/AAC.00896-10. Epub 2010 Jul 26. Antimicrob Agents Chemother. 2010. PMID: 20660687 Free PMC article. Clinical Trial.

Cite

Share

10

Cite

Share

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR. Kullberg BJ, et al. Among authors: schlamm ht. Lancet. 2005 Oct 22-28;366(9495):1435-42. doi: 10.1016/S0140-6736(05)67490-9. Lancet. 2005. PMID: 16243088 Clinical Trial.

Cite

Share